Bristol-Myers Squibb Co Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh BMYB34
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- R$320.62
- Day Range
- R$317.76–317.76
- 52-Week Range
- R$229.45–349.41
- Bid/Ask
- R$0.00 / R$0.00
- Shares Outstanding
- 2.04B
- Market Cap
- R$649.09B
- Volume/Avg
- 1 / 158
Key Statistics
- Price/Earnings (Normalized)
- 9.24
- Price/Sales
- 2.49
- Dividend Yield (Trailing)
- 3.14%
- Dividend Yield (Forward)
- 4.09%
- Dividend Payment Schedule
- Feb, May, Aug, Nov
- Total Yield
- 3.14%
Company Profile
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 32,500
- Website
- https://www.bms.com
Competitors
Valuation
|
Metric
|
BMYB34
|
MRK
|
GSK
|
|---|---|---|---|
Price/Earnings (Normalized) | 9.24 | 45.36 | 11.46 |
Price/Book Value | 5.60 | 8.57 | 3.98 |
Price/Sales | 2.49 | 5.43 | 2.13 |
Price/Cash Flow | 8.26 | 16.30 | 9.11 |
Price/Earnings
BMYB34
MRK
GSK
Financial Strength
|
Metric
|
BMYB34
|
MRK
|
GSK
|
|---|---|---|---|
Quick Ratio | 1.29 | 0.71 | 0.52 |
Current Ratio | 1.53 | 1.32 | 0.82 |
Interest Coverage | 7.88 | 4.28 | 9.51 |
Quick Ratio
BMYB34
MRK
GSK
Profitability
|
Metric
|
BMYB34
|
MRK
|
GSK
|
|---|---|---|---|
Return on Assets (Normalized) | 14.59% | 6.27% | 11.66% |
Return on Equity (Normalized) | 68.67% | 16.68% | 42.98% |
Return on Invested Capital (Normalized) | 21.69% | 9.82% | 22.63% |
Return on Assets
BMYB34
MRK
GSK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|W<y#QNz# | LOCK|>G? | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|&?%%?!% | LOCK|J> | $630B | |||
| AbbVie Inc
ABBV
| LOCK|p$rwh&> | LOCK|vM | $489B | |||
| Merck & Co Inc
MRK
| LOCK|!zPY$<h | LOCK|H> | $359B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|?%%pvD% | LOCK|&Y | $344B | |||
| Novartis AG ADR
NVS
| LOCK|#%<Z#$@ | LOCK|hT | $272B | |||
| AstraZeneca PLC
AZN
| LOCK|M$mnNs#V | LOCK|?J | $246B | |||
| Amgen Inc
AMGN
| LOCK|%n&dWy&p | LOCK|!r | $224B | |||
| Gilead Sciences Inc
GILD
| LOCK|kbv@>x | LOCK|ZP | $187B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|?#R%>z! | LOCK|!&& | $169B |
United States